Toxicogenomics and Drug Monitoring

Biography

Biography: Wafa Soudani

Abstract

Background: The Inhibitors of Receivers with Tyrosin Kinase are new therapeutic targets recently explored with an aim of increasing the selectivity of antitumor action, the main aim was to evaluate the tolerance with the Inhibitors of Receivers with Tyrosin Kinase among cancer patients. Method: A retrospective descriptive study was carried out into a series of thirty-three case (33) cancer patients reached of chronic Leukemia myeloid follow-ups on the service of hemato -oncology CHU Annaba during December 2013 to April 2014. Results & Discussion: The study of the tolerance showed that Imatinib: Glivec® gave only one case with complications colopathy type and respiratory allergy; with disappearance of the osseous pains and the arterial hypertension obtained with Imatinib: Imatib®; what confirms a good tolerance of the specialty of Glivec® compared to Imatib®. We did not note any complication for Dasatinib and Nilotinib, with reduction in the specific effects (Dasatinib gave 16.67% of the osseous pains, Nilotinib 9.09% of osseous pains and 9.09% of myalgia), reduction in the asthenia (33.33% for Dasatinib and 9.09% for Nilotinib); this testifies to a better tolerance of the new inhibiting molecules of receivers with Tyrosin Kinase Dasatinib and Nilotinib compared to the molecule of reference Imatinib. Conclusion: Through these data we raise the interest of selection of the therapeutic protocols and the importance of a strict monitoring of the undesirable effects of therapeutic targeted in order to ensure better followed therapeutic for the cancer patients.